<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00413634</url>
  </required_header>
  <id_info>
    <org_study_id>SPD422-203</org_study_id>
    <secondary_id>2004-004058-20</secondary_id>
    <nct_id>NCT00413634</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET)</brief_title>
  <official_title>A Phase II, Open-label, Multicentre, Pharmacokinetic, Pharmacodynamic and Safety Study of Anagrelide Hydrochloride in Young (18-50 Years) and Elderly (≥ 65 Years) Patients With Essential Thrombocythaemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <brief_summary>
    <textblock>
      Age related differences in response to a drug could arise from variation in pharmacokinetic
      (PK) and/or pharmacodynamic (PD) profiles between age groups. Whilst the efficacy and safety
      profile of anagrelide is well established through a well-documented clinical trial programme
      in patients of all ages, no formal studies have been carried out to investigate whether the
      PK profile of anagrelide and its metabolites is altered with age.

      This study is designed to allow comparisons to be made in terms of pharmacokinetics of
      anagrelide and its metabolites between elderly (≥ 65 years) and young (18-50 years) ET
      patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Agrylin</measure>
    <time_frame>over 1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Maximum Plasma Concentration (Tmax) of Agrylin</measure>
    <time_frame>over 1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Agrylin</measure>
    <time_frame>over 1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-life (T 1/2) of Agrylin</measure>
    <time_frame>over 1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Clearance (CL/F) of Agrylin</measure>
    <time_frame>over 1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of Distribution (Vz/F) of Agrylin</measure>
    <time_frame>over 1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Active Metabolite</measure>
    <time_frame>over 1 day</time_frame>
    <description>An active metabolite has therapeutic activity similar to the parent compound and must be considered in therapeutic pharmacokinetics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Active Metabolite</measure>
    <time_frame>over 1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of Active Metabolite</measure>
    <time_frame>over 1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T 1/2 of Active Metabolite</measure>
    <time_frame>over 1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of Active Metabolite</measure>
    <time_frame>over 1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F of Active Metabolite</measure>
    <time_frame>over 1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet Count</measure>
    <time_frame>over 1 day</time_frame>
    <description>Platelet counts in patients with ET receiving Agrylin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>over 1 day</time_frame>
    <description>Heart rates in patients with ET receiving Agrylin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>over 1 day</time_frame>
    <description>Systolic blood pressures in patients with ET receiving Agrylin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>over 1 day</time_frame>
    <description>Diastolic blood pressures in patients with ET receiving Agrylin</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Essential Thrombocythaemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anagrelide hydrochloride</intervention_name>
    <description>Anagrelide hydrochloride 0.5 mg per capsule; patients will be stable on an anagrelide treatment regimen and will take capsules from their own prescription except on the PK day when the patient specific anagrelide dose will be administered from a controlled study specific supply.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Young patients aged 18-50 years inclusive or Elderly patients aged 65 years and over

          -  Patients must have a confirmed diagnosis of ET.

          -  Currently receiving anagrelide hydrochloride at a stable maintenance dose &lt; 5 mg/day
             for at least 4 weeks.

        Exclusion Criteria:

          -  Diagnosis of any other myeloproliferative disorder.

          -  Current use of tobacco in any form (e.g. smoking or chewing)

          -  Treatment with any known enzyme altering agents (barbiturates, phenothiazines,
             cimetidine etc.) within 30 days prior to or during the study.

          -  Patients for whom use of another cytoreductive agent in addition to anagrelide is
             considered necessary for control of platelet count.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Besses Raebel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospitl Del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quintiles Hermelinen</name>
      <address>
        <city>Sandviksgatan</city>
        <state>Lulea</state>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quintiles AB Phase I Unit</name>
      <address>
        <city>Strandbodgatan</city>
        <state>Uppsala</state>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala Akademiska Sjukhus</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020333s015lbl.pdf</url>
    <description>FDA-approved Label</description>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>FDA Recall Information</description>
  </link>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2006</study_first_submitted>
  <study_first_submitted_qc>December 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2006</study_first_posted>
  <results_first_submitted>March 5, 2009</results_first_submitted>
  <results_first_submitted_qc>April 8, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 2, 2009</results_first_posted>
  <last_update_submitted>June 6, 2014</last_update_submitted>
  <last_update_submitted_qc>June 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2014</last_update_posted>
  <responsible_party>
    <name_title>Timothy Whitaker, M.D.</name_title>
    <organization>Shire</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anagrelide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were between 18-50 years (young) and 65 or older (elderly) with a diagnosis of essential thrombocythemia (ET) and receiving a stable dose of anagrelide &lt;=5mg/day for at least 4 weeks.</recruitment_details>
      <pre_assignment_details>The study comprised four phases: Screening (patients take their normal regimen of anagrelide), a run-in period (patients divided their normal anagrelide daily dose equally into two daily doses), Pharmacokinetics (PK) sampling day (patients take normal morning dose), and follow-up (patients were contacted by phone 30 days after PK visit).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Agrylin (Young)</title>
          <description>Anagrelide hydrochloride in ages 18-50 years</description>
        </group>
        <group group_id="P2">
          <title>Agrylin (Elderly)</title>
          <description>Anagrelide hydrochloride in ages 65 and older</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Agrylin (Young)</title>
          <description>Anagrelide hydrochloride in ages 18-50 years</description>
        </group>
        <group group_id="B2">
          <title>Agrylin (Elderly)</title>
          <description>Anagrelide hydrochloride in ages 65 and older</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.2" spread="8.4"/>
                    <measurement group_id="B2" value="69.2" spread="3.0"/>
                    <measurement group_id="B3" value="54.2" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of Agrylin</title>
        <time_frame>over 1 day</time_frame>
        <population>PK population (defined as all patients with post-dose drug concentration data)</population>
        <group_list>
          <group group_id="O1">
            <title>Agrylin (Young)</title>
            <description>Anagrelide hydrochloride in ages 18-50 years</description>
          </group>
          <group group_id="O2">
            <title>Agrylin (Elderly)</title>
            <description>Anagrelide hydrochloride in ages 65 and older</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Agrylin</title>
          <population>PK population (defined as all patients with post-dose drug concentration data)</population>
          <units>ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" spread="0.99"/>
                    <measurement group_id="O2" value="3.63" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.092</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Count</title>
        <description>Platelet counts in patients with ET receiving Agrylin</description>
        <time_frame>over 1 day</time_frame>
        <population>Safety population (defined as all patients who received study treatment)</population>
        <group_list>
          <group group_id="O1">
            <title>Agrylin (Young)</title>
            <description>Anagrelide hydrochloride in ages 18-50 years</description>
          </group>
          <group group_id="O2">
            <title>Agrylin (Elderly)</title>
            <description>Anagrelide hydrochloride in ages 65 and older</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Count</title>
          <description>Platelet counts in patients with ET receiving Agrylin</description>
          <population>Safety population (defined as all patients who received study treatment)</population>
          <units>x 1,000,000,000/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="488.8" spread="167.4"/>
                    <measurement group_id="O2" value="548.5" spread="278.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="487.9" spread="168.1"/>
                    <measurement group_id="O2" value="539.2" spread="258.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="473.2" spread="146.0"/>
                    <measurement group_id="O2" value="540.3" spread="263.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate</title>
        <description>Heart rates in patients with ET receiving Agrylin</description>
        <time_frame>over 1 day</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Agrylin (Young)</title>
            <description>Anagrelide hydrochloride in ages 18-50 years</description>
          </group>
          <group group_id="O2">
            <title>Agrylin (Elderly)</title>
            <description>Anagrelide hydrochloride in ages 65 and older</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate</title>
          <description>Heart rates in patients with ET receiving Agrylin</description>
          <population>Safety population</population>
          <units>beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.0" spread="9.6"/>
                    <measurement group_id="O2" value="70.3" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" spread="8.9"/>
                    <measurement group_id="O2" value="77.7" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.8" spread="5.5"/>
                    <measurement group_id="O2" value="80.6" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.1" spread="7.7"/>
                    <measurement group_id="O2" value="82.7" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.3" spread="7.0"/>
                    <measurement group_id="O2" value="81.2" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" spread="5.5"/>
                    <measurement group_id="O2" value="74.7" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.9" spread="8.6"/>
                    <measurement group_id="O2" value="76.9" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5" spread="6.7"/>
                    <measurement group_id="O2" value="76.3" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2" spread="6.0"/>
                    <measurement group_id="O2" value="71.9" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Maximum Plasma Concentration (Tmax) of Agrylin</title>
        <time_frame>over 1 day</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Agrylin (Young)</title>
            <description>Anagrelide hydrochloride in ages 18-50 years</description>
          </group>
          <group group_id="O2">
            <title>Agrylin (Elderly)</title>
            <description>Anagrelide hydrochloride in ages 65 and older</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Plasma Concentration (Tmax) of Agrylin</title>
          <population>PK population</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="0.39"/>
                    <measurement group_id="O2" value="1.14" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.857</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Agrylin</title>
        <time_frame>over 1 day</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Agrylin (Young)</title>
            <description>Anagrelide hydrochloride in ages 18-50 years</description>
          </group>
          <group group_id="O2">
            <title>Agrylin (Elderly)</title>
            <description>Anagrelide hydrochloride in ages 65 and older</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Agrylin</title>
          <population>PK population</population>
          <units>ng.h/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="2.4"/>
                    <measurement group_id="O2" value="10.3" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Half-life (T 1/2) of Agrylin</title>
        <time_frame>over 1 day</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Agrylin (Young)</title>
            <description>Anagrelide hydrochloride in ages 18-50 years</description>
          </group>
          <group group_id="O2">
            <title>Agrylin (Elderly)</title>
            <description>Anagrelide hydrochloride in ages 65 and older</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (T 1/2) of Agrylin</title>
          <population>PK population</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.4"/>
                    <measurement group_id="O2" value="1.4" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.378</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Clearance (CL/F) of Agrylin</title>
        <time_frame>over 1 day</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Agrylin (Young)</title>
            <description>Anagrelide hydrochloride in ages 18-50 years</description>
          </group>
          <group group_id="O2">
            <title>Agrylin (Elderly)</title>
            <description>Anagrelide hydrochloride in ages 65 and older</description>
          </group>
        </group_list>
        <measure>
          <title>Total Clearance (CL/F) of Agrylin</title>
          <population>PK population</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156" spread="73"/>
                    <measurement group_id="O2" value="97" spread="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Volume of Distribution (Vz/F) of Agrylin</title>
        <time_frame>over 1 day</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Agrylin (Young)</title>
            <description>Anagrelide hydrochloride in ages 18-50 years</description>
          </group>
          <group group_id="O2">
            <title>Agrylin (Elderly)</title>
            <description>Anagrelide hydrochloride in ages 65 and older</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution (Vz/F) of Agrylin</title>
          <population>PK population</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="286" spread="125"/>
                    <measurement group_id="O2" value="195" spread="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Active Metabolite</title>
        <description>An active metabolite has therapeutic activity similar to the parent compound and must be considered in therapeutic pharmacokinetics.</description>
        <time_frame>over 1 day</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Agrylin (Young)</title>
            <description>Active metabolite of Agrylin (BCH24426) in ages 18-50</description>
          </group>
          <group group_id="O2">
            <title>Agrylin (Elderly)</title>
            <description>Active metabolite of Agrylin (BCH24426) in ages 65 and older</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Active Metabolite</title>
          <description>An active metabolite has therapeutic activity similar to the parent compound and must be considered in therapeutic pharmacokinetics.</description>
          <population>PK population</population>
          <units>ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.26" spread="3.74"/>
                    <measurement group_id="O2" value="4.19" spread="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Active Metabolite</title>
        <time_frame>over 1 day</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Agrylin (Young)</title>
            <description>Active metabolite of Agrylin (BCH24426) in ages 18-50</description>
          </group>
          <group group_id="O2">
            <title>Agrylin (Elderly)</title>
            <description>Active metabolite of Agrylin (BCH24426) in ages 65 and older</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Active Metabolite</title>
          <population>PK population</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="0.26"/>
                    <measurement group_id="O2" value="1.04" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.557</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC of Active Metabolite</title>
        <time_frame>over 1 day</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Agrylin (Young)</title>
            <description>Active metabolite of Agrylin (BCH24426) in ages 18-50</description>
          </group>
          <group group_id="O2">
            <title>Agrylin (Elderly)</title>
            <description>Active metabolite of Agrylin (BCH24426) in ages 65 and older</description>
          </group>
        </group_list>
        <measure>
          <title>AUC of Active Metabolite</title>
          <population>PK population</population>
          <units>ng.h/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6" spread="10.9"/>
                    <measurement group_id="O2" value="17.4" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T 1/2 of Active Metabolite</title>
        <time_frame>over 1 day</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Agrylin (Young)</title>
            <description>Active metabolite of Agrylin (BCH24426) in ages 18-50</description>
          </group>
          <group group_id="O2">
            <title>Agrylin (Elderly)</title>
            <description>Active metabolite of Agrylin (BCH24426) in ages 65 and older</description>
          </group>
        </group_list>
        <measure>
          <title>T 1/2 of Active Metabolite</title>
          <population>PK population</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.5"/>
                    <measurement group_id="O2" value="3.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CL/F of Active Metabolite</title>
        <time_frame>over 1 day</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Agrylin (Young)</title>
            <description>Active metabolite of Agrylin (BCH24426) in ages 18-50</description>
          </group>
          <group group_id="O2">
            <title>Agrylin (Elderly)</title>
            <description>Active metabolite of Agrylin (BCH24426) in ages 65 and older</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F of Active Metabolite</title>
          <population>PK population</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" spread="16"/>
                    <measurement group_id="O2" value="57" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vz/F of Active Metabolite</title>
        <time_frame>over 1 day</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Agrylin (Young)</title>
            <description>Active metabolite of Agrylin (BCH24426) in ages 18-50</description>
          </group>
          <group group_id="O2">
            <title>Agrylin (Elderly)</title>
            <description>Active metabolite of Agrylin (BCH24426) in ages 65 and older</description>
          </group>
        </group_list>
        <measure>
          <title>Vz/F of Active Metabolite</title>
          <population>PK population</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139" spread="86"/>
                    <measurement group_id="O2" value="277" spread="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure</title>
        <description>Systolic blood pressures in patients with ET receiving Agrylin</description>
        <time_frame>over 1 day</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Agrylin (Young)</title>
            <description>Anagrelide hydrochloride in ages 18-50 years</description>
          </group>
          <group group_id="O2">
            <title>Agrylin (Elderly)</title>
            <description>Anagrelide hydrochloride in ages 65 and older</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>Systolic blood pressures in patients with ET receiving Agrylin</description>
          <population>Safety population</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.2" spread="9.6"/>
                    <measurement group_id="O2" value="154.3" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.7" spread="12.9"/>
                    <measurement group_id="O2" value="145.2" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.8" spread="11.7"/>
                    <measurement group_id="O2" value="143.7" spread="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.3" spread="11.6"/>
                    <measurement group_id="O2" value="140.1" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.3" spread="12.3"/>
                    <measurement group_id="O2" value="139.9" spread="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.2" spread="13.6"/>
                    <measurement group_id="O2" value="133.7" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.2" spread="16.1"/>
                    <measurement group_id="O2" value="141.8" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.6" spread="14.5"/>
                    <measurement group_id="O2" value="136.3" spread="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.7" spread="13.6"/>
                    <measurement group_id="O2" value="159.8" spread="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure</title>
        <description>Diastolic blood pressures in patients with ET receiving Agrylin</description>
        <time_frame>over 1 day</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Agrylin (Young)</title>
            <description>Anagrelide hydrochloride in ages 18-50 years</description>
          </group>
          <group group_id="O2">
            <title>Agrylin (Elderly)</title>
            <description>Anagrelide hydrochloride in ages 65 and older</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <description>Diastolic blood pressures in patients with ET receiving Agrylin</description>
          <population>Safety population</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9" spread="7.5"/>
                    <measurement group_id="O2" value="81.4" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.8" spread="7.3"/>
                    <measurement group_id="O2" value="75.2" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" spread="6.6"/>
                    <measurement group_id="O2" value="72.6" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.8" spread="6.7"/>
                    <measurement group_id="O2" value="71.6" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3" spread="7.9"/>
                    <measurement group_id="O2" value="72.8" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2" spread="6.0"/>
                    <measurement group_id="O2" value="73.0" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4" spread="10.0"/>
                    <measurement group_id="O2" value="71.3" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.3" spread="6.2"/>
                    <measurement group_id="O2" value="75.0" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.3" spread="9.1"/>
                    <measurement group_id="O2" value="84.2" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Agrylin (Young)</title>
          <description>Anagrelide hydrochloride in ages 18-50 years</description>
        </group>
        <group group_id="E2">
          <title>Agrylin (Elderly)</title>
          <description>Anagrelide hydrochloride in ages 65 and older</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Timothy Whitaker, M.D.</name_or_title>
      <organization>Shire</organization>
      <email>twhitaker@shire.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

